A Phase 4 interventional study of Antihemophilic factor, recombinant, manufactured protein-free and Antihemophilic factor, recombinant, manufactured protein-free in Hemophilia A, sponsored by Baxalta now part of Shire. Completed at 29 sites in 10 countries. Open to participants aged 7 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-05-19.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.
Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 3rd largest by enrollment, is one of 2 that started in 2006, is one of 8 in phase 4, and was the 4th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:
Runhui WU · Sites in China
Ages 0–18 · Men only
By country, each count listing its studies:
antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 7 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 7 · Phase 4 8
First in 2001; this study’s year is marked. 2 started in 2006.
This study's enrollment of 82 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 50 across the 21 interventional studies. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
47 studies in Hemophilia A by Takeda: none open now, 1 under way, none of them phase 3. Of 46 finished, 27 (59%) have results posted.
Among the 47 studies in Hemophilia A by Takeda, this one is the 6th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2006, is one of 7 in phase 4, and was the 8th registered.
Takeda’s Hemophilia A studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 47 in Hemophilia A:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this randomized, two-arm parallel clinical study in 66 previously treated patients with severe or moderately severe hemophilia A is to compare the rate of bleeding episodes for standard prophylaxis (20-40 IU/kg every 48 ± 6 hours; actual dose determined by the investigator) with that of alternate prophylaxis (20-80 IU/kg every 72 + 6 hours; actual dose determined by Baxter utilizing an algorithm and the patient's pharmacokinetic data). The rates of bleeding episodes for the on-demand regimen and the prophylaxis regimens will also be compared for the cross-over portion of the study. Enrolled patients will be treated originally on demand for a period of 6 months and then they will be randomized into one of the prophylaxis arms. Prophylactic treatment will last for a period of 12 months +/- 2 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard prophylaxis
Drug: Antihemophilic factor, recombinant, manufactured protein-free
PK-driven prophylaxis
Drug: Antihemophilic factor, recombinant, manufactured protein-free
Drug pages: Antihemophilic factor, human recombinant · F8 protein, human
Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator
Drug pages: Antihemophilic factor, human recombinant · F8 protein, human
PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data
Mean Transformed Annualized Bleed Rate Estimates From Each of the 1-year Prophylaxis Regimens
Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Study Part 2): 1. Standard prophylaxis (20-40 IU/kg (every 48 ±6 hour), exact regimen determined by investigator) 2. PK-driven prophylaxis (20-80 IU/kg (every 72 ±6 hour), exact regimen determined by sponsor) Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X = bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the t-test.
Time frame: 12 months ±2 weeks
Median Annualized Bleed Rate Estimates From Each of the 1 Year Prophylaxis Regimens
Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Part 2 of the study): 1. Standard prophylaxis- infusions every 48 ±6 hours, dosed at 20 to 40 IU/kg. 2. PK-driven prophylaxis- infusions every 72 ±6 hours dosed at 20 to 80 IU/kg.
Time frame: 12 months ±2 weeks
Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Standard Prophylaxis Treatment Regimens
Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test. Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (Standard Prophylaxis Treatment TABR). Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).
Time frame: On-demand 6 months (± 2 weeks); followed by Prophylaxis 12 months (± 2 weeks)
Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and PK-Driven Prophylaxis Treatment Regimens
Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test. Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (PK-Driven Prophylaxis Treatment TABR) Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).
Time frame: On-demand 6 months (± 2 weeks); followed by Prophylaxis 12 months (± 2 weeks)
Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Any Prophylaxis Treatment Regimens
Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test. Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (Any Prophylaxis Treatment TABR). Any Prophylaxis = Standard or PK-Driven Prophylaxis Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).
Time frame: On-demand 6 months (± 2 weeks); Prophylaxis 12 months (± 2 weeks)
Total Weight-Adjusted Dose of rAHF-PFM Used Per Year for Each Prophylaxis Arm
Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Part 2 of the study): 1. Standard prophylaxis- infusions every 48 ±6 hours, dosed at 20 to 40 IU/kg. 2. PK-driven prophylaxis- infusions every 72 ±6 hours dosed at 20 to 80 IU/kg.
Time frame: 12 months ±2 weeks
Bleeding Episodes Treated With 1 to ≥4 Infusions
The number of bleeding episodes treated with 1, 2, 3, or ≥4 infusions of rAHF-PFM to achieve adequate hemostasis
Time frame: Throughout the study period (4 years and 5 months)
Assessment of Hemostasis for Treatment of Bleeding Episodes
Number of rAHF-PFM-treated bleeding episodes with an assessment of hemostasis (4-point ordinal scale): Excellent: Full pain relief \& bleeding cessation within \~8 hrs of 1 infusion. Additional infusions may have been given to maintain hemostasis; Good: Definite pain relief and/or improvement in bleeding within \~8 hrs after infusion. Possibly requires \>1 infusion for complete resolution; Fair: Probable or slight relief of pain \& slight improvement in bleeding within \~8 hrs after infusion. Requires \>1 infusion for complete resolution; None: No improvement or condition worsens
Time frame: On-demand 6 months (± 2 weeks); Prophylaxis 12 months (± 2 weeks)
Total Area Under the Curve (AUC)
Total AUC estimated by AUC 0-48h plus an area extrapolated from the log-linear regression model
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Area Under the Curve
Area under the factor VIII (FVIII) plasma concentration versus time curve (AUC) from 0 to 48 hours estimated using the linear trapezoidal method
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Maximum Plasma Concentration (C-max)
Maximal Factor VIII Concentration After Infusion
Time frame: Within 1 hour post-infusion
Adjusted Incremental Recovery (IR)
Change in factor VIII concentration from pre- to post-infusion at initial and termination study visits. Adjusted IR defined as: \[Cmax (IU/dL) - pre-infusion FVIII (IU/dL)\]/dose (IU/kg)
Time frame: 30 minutes pre-infusion to 48 hours post-infusion
Terminal Half-life
Computed from the regression slope in the terminal phase of the model. Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Weight-Adjusted Clearance
Computed as the weight-adjusted dose divided by total AUC
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Mean Residence Time
Computed as total Area Under the Moment Curve (AUMC) divided by the total AUC
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Volume of Distribution at Steady State
Computed as weight-adjusted clearance \* mean residence time
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Factor VIII Inhibitor Development
Number of treated participants who developed factor VIII inhibitors
Time frame: Throughout study period (4 years and 5 months)
Number of Participants With AEs Related to Investigational Product (IP)
Number of treated participants with AEs judged to be possibly or probably related to treatment with IP
Time frame: Throughout study period (4 years and 5 months)
Number of Participants Who Reported ≥1 AE Regardless of Relatedness to Investigational Product (IP)
Number of treated participants with 1 or more AE regardless of relatedness to IP
Time frame: Throughout study period (4 years and 5 months)
Number of Participants Who Reported ≥1 AE Regardless of Relatedness to IP by Treatment Regimen
Time frame: Throughout the study period (4 years and 5 months)
Number of Participants With SAEs by Preferred MedDRA Term and Treatment Regimen
Time frame: Throughout the study period (4 years and 5 months)
AEs With Onset ≤1 Hour Following the End of an Infusion, Regardless of Relatedness
Time frame: Throughout study period (4 years and 5 months)
Number of Participants With Severe SAEs and Severe Non-SAEs by Preferred MedDRA Term and Treatment Regimen
This outcome is focused only on SEVERE SAEs and SEVERE non-SAEs
Time frame: Throughout the study period (4 years and 5 months)
Baseline Health-related Quality of Life (HRQoL) Scores: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS
Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Baseline SF-36v1 Scores, where data available. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.
Time frame: Baseline
Health-related Quality of Life (HRQoL) Scores: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS at the End of Treatment Regimens
Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Baseline SF-36v1 Scores, where data available. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.
Time frame: End of on-demand treatment period (6 months) and at study termination (approximately 18 months)
HRQoL Scores Change From On-Demand Treatment Regimen Period Through Prophylaxis Period
Differences in health domain scores = (End of on-demand treatment) - (End of prophylaxis regimen). A negative value for the median difference equates to a larger domain score for the prophylaxis regimen Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.
Time frame: End of on-demand treatment period (6 months) and at study termination (approximately 18 months)
Bodily Pain HRQoL Scores Change From On-Demand Period Through Prophylaxis Period
Change = (End of on-demand treatment) - (End of prophylaxis regimen). A negative value for the median difference equates to a larger domain score for the prophylaxis regimen. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores.
Time frame: End of on-demand treatment period (6 months) and at study termination (approximately 18 months)
Physical Component Scores (PCS) HRQoL Scores Change From On-Demand Period Through Prophylaxis Period
Change = (End of on-demand treatment) - (End of prophylaxis regimen) A negative value for the median difference equates to a larger domain score for the prophylaxis regimen. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores.
Time frame: End of on-demand treatment period (6 months) and at study termination (approximately 18 months)
Participants were enrolled at 21 European and 9 United States clinical sites beginning January 2006 and completing in June 2010
| Milestone | All Study Participants | PK-Driven Prophylaxis | Standard Prophylaxis |
|---|---|---|---|
| Started | 73 | 0 | 0 |
| Completed | 69 | 0 | 0 |
| Not completed | 4 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Screen failures | 2 | 0 | 0 |
| Milestone | All Study Participants | PK-Driven Prophylaxis | Standard Prophylaxis |
|---|---|---|---|
| Started | 69 | 0 | 0 |
| Completed | 66 | 0 | 0 |
| Not completed | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Withdrawn for non-compliance | 1 | 0 | 0 |
| Milestone | All Study Participants | PK-Driven Prophylaxis | Standard Prophylaxis |
|---|---|---|---|
| Started | 0 | 34 | 32 |
| Completed | 0 | 31 | 32 |
| Not completed | 0 | 3 | 0 |
| Withdrew: Withdrawn for non-compliance | 0 | 2 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Study Part 2): 1. Standard prophylaxis (20-40 IU/kg (every 48 ±6 hour), exact regimen determined by investigator) 2. PK-driven prophylaxis (20-80 IU/kg (every 72 ±6 hour), exact regimen determined by sponsor) Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X = bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the t-test.
| (bleeds/year)^(1/2) | PK-Driven Prophylaxis | Standard Prophylaxis |
|---|---|---|
| Mean Transformed Annualized Bleed Rate Estimates From Each of the 1-year Prophylaxis Regimens | 1.61 ± 1.10 | 1.46 ± 0.98 |
Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test. Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (Standard Prophylaxis Treatment TABR). Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).
| (bleeds/year)^(1/2) | On-Demand Versus Standard Prophylaxis |
|---|---|
| Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Standard Prophylaxis Treatment Regimens | 5.29 ± 1.46 |
Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test. Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (PK-Driven Prophylaxis Treatment TABR) Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).
| (bleeds/year)^(1/2) | On-Demand Versus PK-Driven Prophylaxis |
|---|---|
| Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and PK-Driven Prophylaxis Treatment Regimens | 5.00 ± 1.85 |
Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test. Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (Any Prophylaxis Treatment TABR). Any Prophylaxis = Standard or PK-Driven Prophylaxis Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).
| (bleeds/year)^(1/2) | On-Demand Versus Any Prophylaxis |
|---|---|
| Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Any Prophylaxis Treatment Regimens | 5.14 ± 1.66 |
Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Part 2 of the study): 1. Standard prophylaxis- infusions every 48 ±6 hours, dosed at 20 to 40 IU/kg. 2. PK-driven prophylaxis- infusions every 72 ±6 hours dosed at 20 to 80 IU/kg.
| IU/kg | PK-Driven Prophylaxis | Standard Prophylaxis |
|---|---|---|
| Total Weight-Adjusted Dose of rAHF-PFM Used Per Year for Each Prophylaxis Arm | 5197.8 (3268.4 to 8273.5) | 5768.2 (4728.0 to 6425.4) |
The number of bleeding episodes treated with 1, 2, 3, or ≥4 infusions of rAHF-PFM to achieve adequate hemostasis
| Bleeding episodes | On-Demand Treatment | Standard Prophylaxis Treatment | PK-Driven Prophylaxis |
|---|---|---|---|
| 1 infusion (n = 62, 13, 22) | 1168 | 68 | 90 |
| 2 infusions (n = 51, 6, 9) | 277 | 12 | 37 |
| 3 infusions (n = 27, 2, 4) | 128 | 4 | 5 |
| 4 or more infusions (n = 21, 5, 5) | 50 | 9 | 7 |
Number of rAHF-PFM-treated bleeding episodes with an assessment of hemostasis (4-point ordinal scale): Excellent: Full pain relief \& bleeding cessation within \~8 hrs of 1 infusion. Additional infusions may have been given to maintain hemostasis; Good: Definite pain relief and/or improvement in bleeding within \~8 hrs after infusion. Possibly requires \>1 infusion for complete resolution; Fair: Probable or slight relief of pain \& slight improvement in bleeding within \~8 hrs after infusion. Requires \>1 infusion for complete resolution; None: No improvement or condition worsens
| bleeding episodes | On-Demand Regimen | Standard Prophylaxis | PK-Driven Prophylaxis |
|---|---|---|---|
| Excellent | 547 | 39 | 33 |
| Good | 943 | 38 | 75 |
| Fair | 167 | 16 | 11 |
| None | 3 | 0 | 20 |
| Unknown | 13 | 0 | 0 |
Total AUC estimated by AUC 0-48h plus an area extrapolated from the log-linear regression model
| IU*h/dL | ≥14 Years of Age | <14 Years of Age |
|---|---|---|
| Total Area Under the Curve (AUC) | 1334.45 ± 454.33 | 1061.26 ± 452.87 |
Area under the factor VIII (FVIII) plasma concentration versus time curve (AUC) from 0 to 48 hours estimated using the linear trapezoidal method
| IU*h/dL | ≥14 Years of Age | <14 Years of Age |
|---|---|---|
| Area Under the Curve | 1213.98 ± 323.96 | 966.68 ± 330.83 |
Maximal Factor VIII Concentration After Infusion
| IU/dL | ≥14 Years of Age | <14 Years of Age |
|---|---|---|
| Maximum Plasma Concentration (C-max) | 91.12 ± 20.15 | 74.47 ± 11.30 |
Change in factor VIII concentration from pre- to post-infusion at initial and termination study visits. Adjusted IR defined as: \[Cmax (IU/dL) - pre-infusion FVIII (IU/dL)\]/dose (IU/kg)
| IU/dL per IU/kg | ≥14 Years of Age | <14 Years of Age |
|---|---|---|
| Adjusted Incremental Recovery (IR) | 1.81 ± 0.41 | 1.47 ± 0.27 |
Computed from the regression slope in the terminal phase of the model. Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.
| hours | ≥14 Years of Age | <14 Years of Age |
|---|---|---|
| Terminal Half-life | 13.91 ± 5.07 | 14.66 ± 5.21 |
Computed as the weight-adjusted dose divided by total AUC
| mL/(kg*h) | ≥14 Years of Age | <14 Years of Age |
|---|---|---|
| Weight-Adjusted Clearance | 3.89 ± 1.21 | 5.17 ± 1.94 |
Computed as total Area Under the Moment Curve (AUMC) divided by the total AUC
| hours | ≥14 Years of Age | <14 Years of Age |
|---|---|---|
| Mean Residence Time | 17.71 ± 7.16 | 17.88 ± 5.67 |
Computed as weight-adjusted clearance \* mean residence time
| dL/kg | ≥14 Years of Age | <14 Years of Age |
|---|---|---|
| Volume of Distribution at Steady State | 0.65 ± 0.19 | 0.84 ± 0.19 |
Number of treated participants who developed factor VIII inhibitors
| Participants | All Study Participants |
|---|---|
| Factor VIII Inhibitor Development | 0 |
Number of treated participants with AEs judged to be possibly or probably related to treatment with IP
| Participants | All Study Participants |
|---|---|
| Number of Participants With AEs Related to Investigational Product (IP) | 4 |
Number of treated participants with 1 or more AE regardless of relatedness to IP
| Participants | All Study Participants |
|---|---|
| Number of Participants Who Reported ≥1 AE Regardless of Relatedness to Investigational Product (IP) | 44 |
| participants | On-Demand | Standard Prophylaxis | PK-Driven Prophylaxis |
|---|---|---|---|
| Number of Participants Who Reported ≥1 AE Regardless of Relatedness to IP by Treatment Regimen | 33 | 15 | 19 |
| participants | On-Demand | Standard Prophylaxis | PK-Driven Prophylaxis | SAEs Outside of the 3 Treatment Arms |
|---|---|---|---|---|
| ABDOMINAL PAIN | 1 | 0 | 0 | 0 |
| NAUSEA | 1 | 0 | 0 | 0 |
| TOOTH ABSCESS | 1 | 0 | 0 | 0 |
| JOINT DISLOCATION | 1 | 0 | 0 | 0 |
| HAEMOPHILIC ARTHROPATHY | 1 | 0 | 1 | 0 |
| SYNOVITIS | 1 | 0 | 0 | 0 |
| CALCULUS URINARY | 1 | 0 | 0 | 0 |
| HOSPITALIZATION | 1 | 0 | 0 | 0 |
| PULPITIS DENTAL | 0 | 1 | 0 | 0 |
| SOMNAMBULISM | 0 | 1 | 0 | 0 |
| FACTOR VIII INHIBITION (UNCONFIRMED) | 0 | 0 | 1 | 0 |
| APPENDICITIS | 0 | 0 | 1 | 0 |
| PAIN IN EXTREMITY | 0 | 0 | 0 | 1 |
| Events | All Study Participants |
|---|---|
| AEs With Onset ≤1 Hour Following the End of an Infusion, Regardless of Relatedness | 39 |
This outcome is focused only on SEVERE SAEs and SEVERE non-SAEs
| participants | On-Demand | Standard Prophylaxis | PK-Driven Prophylaxis |
|---|---|---|---|
| TOOTH ABSCESS (SAE) | 1 | 0 | 0 |
| HAEMOPHILIC ARTHROPATHY (SAE) | 0 | 0 | 1 |
| HAEMOPHILIC ARTHROPATHY (non-SAE) | 1 | 0 | 1 |
| ABDOMINAL PAIN (non-SAE) | 1 | 0 | 0 |
| ARTHRALGIA (non-SAE) | 1 | 0 | 0 |
Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Baseline SF-36v1 Scores, where data available. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.
| Scores on a scale | Assessed Before Treatment |
|---|---|
| Physical Functioning (PF) | 44.56 (17.29 to 57.14) |
| Role-Physical (RP) | 42.10 (27.95 to 56.24) |
| Bodily Pain (BP) | 46.48 (25.07 to 62.75) |
| General Health (GH) | 43.87 (19.52 to 64.00) |
| Vitality (VT) | 51.42 (25.39 to 67.20) |
| Social Functioning (SF) | 46.28 (19.14 to 57.14) |
| Role-Emotional (RE) | 55.34 (23.74 to 55.34) |
| Mental Health (MH) | 50.44 (20.91 to 64.07) |
| Physical Component Score (PCS) | 42.32 (20.10 to 67.67) |
| Mental Component Score (MCS) | 52.65 (22.56 to 68.10) |
Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Baseline SF-36v1 Scores, where data available. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.
| Scores on a scale | On-Demand Treatment | Standard Prophylaxis | PK-Driven Prophylaxis | Any Prophylaxis Treatment |
|---|---|---|---|---|
| Bodily Pain (BP) | 46.5 (29.4 to 62.8) | 51.6 (19.9 to 62.8) | 51.6 (29.4 to 62.8) | 51.6 (19.9 to 62.8) |
| General Health (GH) | 43.9 (19.5 to 64.0) | 48.6 (19.5 to 64.0) | 46.2 (29.8 to 60.3) | 48.6 (19.5 to 64.0) |
| Mental Component Score (MCS), On-Demand n=62 | 54.9 (22.8 to 69.9) | 56.1 (13.3 to 69.6) | 54.5 (11.4 to 62.5) | 55.0 (11.4 to 69.6) |
| Mental Health (MH), On-Demand n=62 | 51.6 (14.1 to 64.1) | 50.4 (20.9 to 64.1) | 52.7 (7.3 to 64.1) | 50.4 (7.3 to 64.1) |
| Physical Component Score (PCS), On-Demand n=62 | 44.0 (16.1 to 61.2) | 50.2 (17.6 to 68.8) | 47.3 (25.3 to 62.3) | 47.8 (17.6 to 68.8) |
| Physical Functioning (PF), On-Demand n=62 | 48.8 (17.3 to 57.1) | 46.7 (21.5 to 57.1) | 46.7 (17.3 to 57.1) | 46.7 (17.3 to 57.1) |
| Role Emotional (RE) | 55.3 (23.7 to 55.3) | 55.3 (23.7 to 55.3) | 55.3 (23.7 to 55.3) | 55.3 (23.7 to 55.3) |
| Role Physical (RP) | 49.2 (28.0 to 56.2) | 56.2 (28.0 to 56.2) | 56.2 (28.0 to 56.2) | 56.2 (28.0 to 56.2) |
| Social Functioning (SF) | 46.3 (30.0 to 57.1) | 51.7 (24.6 to 57.1) | 51.7 (13.7 to 57.1) | 51.7 (13.7 to 57.1) |
| Vitality (VT) | 53.8 (32.5 to 70.4) | 56.2 (27.8 to 70.4) | 56.2 (23.0 to 68.0) | 56.2 (23.0 to 70.4) |
Differences in health domain scores = (End of on-demand treatment) - (End of prophylaxis regimen). A negative value for the median difference equates to a larger domain score for the prophylaxis regimen Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.
| Scores on a scale | On-Demand to Standard Prophylaxis | On-Demand to PK-Driven Prophylaxis | On-Demand to Any Prophylaxis Treatment |
|---|---|---|---|
| Physical Functioning (PF) | 0.00 (-10.48 to 14.68) | -2.10 (-18.88 to 20.97) | -2.10 (-18.88 to 20.97) |
| Role Physical (RP) | 0.00 (-28.29 to 21.21) | 0.00 (-28.29 to 28.29) | 0.00 (-28.29 to 28.29) |
| Bodily Pain (BP) | 0.00 (-29.55 to 17.55) | -4.29 (-25.27 to 13.28) | 0.00 (-29.55 to 17.55) |
| General Health (GH) | -3.74 (-29.55 to 17.55) | -2.34 (-21.07 to 18.73) | -2.34 (-20.13 to 17.79) |
| Vitality (VT) | 0.00 (-9.47 to 23.67) | 0.00 (-16.57 to 30.77) | 0.00 (-16.57 to 30.77) |
| Social Functioning (SF) | 0.00 (-21.72 to 16.29) | 0.00 (-16.29 to 16.29) | 0.00 (-21.72 to 16.29) |
| Role Emotional (RE) | 0.00 (-10.53 to 31.60) | 0.00 (-31.60 to 21.07) | 0.00 (-31.60 to 31.60) |
| Mental Health (MH) | 0.00 (-13.63 to 15.90) | -1.13 (-40.90 to 34.08) | 0.00 (-40.90 to 34.08) |
| Physical Component Score (PCS) | -2.55 (-20.22 to 8.69) | -3.14 (-16.78 to 19.70) | -2.76 (-20.22 to 19.70) |
| Mental Component Score (MCS) | 1.52 (-8.31 to 21.64) | 0.79 (-35.25 to 24.56) | 1.30 (-35.25 to 24.56) |
Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Part 2 of the study): 1. Standard prophylaxis- infusions every 48 ±6 hours, dosed at 20 to 40 IU/kg. 2. PK-driven prophylaxis- infusions every 72 ±6 hours dosed at 20 to 80 IU/kg.
| Bleeds per year | PK-Driven Prophylaxis | Standard Prophylaxis |
|---|---|---|
| Median Annualized Bleed Rate Estimates From Each of the 1 Year Prophylaxis Regimens | 2.01 (0.00 to 17.06) | 1.00 (0.00 to 25.87) |
Change = (End of on-demand treatment) - (End of prophylaxis regimen). A negative value for the median difference equates to a larger domain score for the prophylaxis regimen. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores.
| Scores on a scale | ≥14 Years of Age |
|---|---|
| Bodily Pain HRQoL Scores Change From On-Demand Period Through Prophylaxis Period | 0.00 (-29.55 to 17.55) |
Change = (End of on-demand treatment) - (End of prophylaxis regimen) A negative value for the median difference equates to a larger domain score for the prophylaxis regimen. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores.
| Scores on a scale | ≥14 Years of Age |
|---|---|
| Physical Component Scores (PCS) HRQoL Scores Change From On-Demand Period Through Prophylaxis Period | -2.76 (-20.22 to 19.70) |
Bleed rates (number of bleeding episodes per subject) were annualized to account for the varying number of days a subject may have actually been on each regimen.
| Bleeding episodes | On-Demand Regimen | Standard Prophylaxis | PK-driven Prophylaxis | Any Prophylaxis |
|---|---|---|---|---|
| Median (IQR) Annualized Bleed Rates | 43.98 (35.73 to 56.53) | 0.99 (0.00 to 2.14) | 1.00 (0.00 to 4.08) | 1.00 (0.00 to 4.07) |
Collected over Throughout the study period (4 years and 5 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| On-Demand | — | 7/73 (9.6%) | 18/73 (24.7%) |
| Standard Prophylaxis | — | 2/32 (6.3%) | 4/32 (12.5%) |
| PK-Driven Prophylaxis | — | 3/34 (8.8%) | 7/34 (20.6%) |
| SAEs Outside of the 3 Treatment Arms | — | 1/1 (100%) | 0/1 (0%) |
| Event | On-Demand | Standard Prophylaxis | PK-Driven Prophylaxis | SAEs Outside of the 3 Treatment Arms |
|---|---|---|---|---|
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 0/73 | 0/32 | 0/34 | 1/1 |
| PULPITIS DENTALInfections and infestations | 0/73 | 1/32 | 0/34 | 0/1 |
| SOMNAMBULISMPsychiatric disorders | 0/73 | 1/32 | 0/34 | 0/1 |
| HAEMOPHILIC ARTHROPATHYMusculoskeletal and connective tissue disorders | 1/73 | 0/32 | 1/34 | 0/1 |
| FACTOR VIII INHIBITIONBlood and lymphatic system disorders | 0/73 | 0/32 | 1/34 | 0/1 |
| APPENDICITISInfections and infestations | 0/73 | 0/32 | 1/34 | 0/1 |
| ABDOMINAL PAINGastrointestinal disorders | 1/73 | 0/32 | 0/34 | 0/1 |
| NAUSEAGastrointestinal disorders | 1/73 | 0/32 | 0/34 | 0/1 |
| TOOTH ABSCESSInfections and infestations | 1/73 | 0/32 | 0/34 | 0/1 |
| JOINT DISLOCATIONInjury, poisoning and procedural complications | 1/73 | 0/32 | 0/34 | 0/1 |
| Event | On-Demand | Standard Prophylaxis | PK-Driven Prophylaxis | SAEs Outside of the 3 Treatment Arms |
|---|---|---|---|---|
| HEADACHENervous system disorders | 4/73 | 0/32 | 3/34 | 0/1 |
| NASOPHARYNGITISInfections and infestations | 6/73 | 0/32 | 0/34 | 0/1 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 0/73 | 2/32 | 0/34 | 0/1 |
| COUGHRespiratory, thoracic and mediastinal disorders | 0/73 | 2/32 | 0/34 | 0/1 |
| IRRITABLE BOWEL SYNDROMEGastrointestinal disorders | 0/73 | 0/32 | 2/34 | 0/1 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 4/73 | 0/32 | 2/34 | 0/1 |
| DIARRHOEAGastrointestinal disorders | 4/73 | 0/32 | 0/34 | 0/1 |
| Age, Continuous(years) | All Study Participants |
|---|---|
| Median | 26 (7 to 59) |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 0 |
| Male | 73 |
Ran from Jan 2006 to primary completion in Jun 2010, 53 months.
Results were first posted in Nov 2012, 2 years 5 months after primary completion. A results delay was requested in Jun 2011.
Of 40 phase 4 interventional studies under Hemophilia A, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 112. This study's 53 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Antihemophilic factor, human recombinant · F8 protein, human